A short social clip from a fitness creator comparing two people on the same medication and why their outcomes differ.
Recap by typeshit. Video by @willknowsfitness on TikTok.
Kalkine Media ties the attention on Lilly to orforglipron's progress, arguing a pill could scale cheaper than injectables and ease supply limits.
Smaller portions could become more common on shelves, with inflation and GLP-1 appetite changes both pushing food makers toward personal packs.
Chokshi notes the sales were 0.4% of Lilly's $23 billion quarter, and that Divi's Labs hasn't announced any role in making the drug.
Oral Wegovy brought in about $850 million in H1 2026 and holds over 80% of new US oral scripts. Lilly says Foundayo volume doubled in a month.
35:20
Manuel Enrique runs a second 50 day stretch on peptides and reports how it went. These are personal claims, not established results.
In a NOLA.com guest column, Vidrine asks Sen. Bill Cassidy and FDA nominee Heidi Overton to tackle social media algorithms pushing unregulated injectables to minors.
Loading…